Clinical Trial Update: A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795 [Phase 1]

View source ↗

Summary

This Phase 1, dose-escalation study of subcutaneously administered JNJ-75220795 has completed in patients with non-alcoholic fatty liver disease, with results f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• JNJ-75220795

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Fatty Liver Disease | Phase 1 | Status: COMPLETED